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1Department of Urology, Daping Hospital, Army Medical University, Chongqing, China, 2Department of Bio-Medical
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Epithelial-to-mesenchymal transition (EMT) is one of the important underlying molecular
mechanisms for most types of cancers including bladder cancer. The precise underlying
molecular mechanism in EMT-mediated bladder cancer progression is far from
completed. LSD1, a histone lysine-specific demethylase, is known to promote cancer cell
proliferation, metastasis, and chemoresistance. We found in this study that LSD1 is highly
upregulated in bladder cancer specimens, especially those underwent chemotherapy,
and the elevated levels of LSD1 are highly associated with bladder cancer grades,
metastasis status, and prognosis. Inhibiting or knockdown LSD1 repressed not only EMT
process but also cancer progression. Mechanistically, LSD1 complexes with β-catenin
to transcriptionally upregulate LEF1 and subsequently enhances EMT-mediated cancer
progression. More importantly, LSD1 specific inhibitor GSK2879552 is capable of
repressing tumor progression in patient-derived tumor xenograft. These findings
altogether suggest that LSD1 can serve as not only a prognostic biomarker but also
a promising therapeutic target in bladder cancer treatment.
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INTRODUCTION
Bladder cancer (BCa) is one of the most frequently diagnosed cancers worldwide with about
429,800 new cases and 165,100 deaths annually (1). Epithelial-mesenchymal transition (EMT) plays
an important role in recurrence, chemoresistance, and progression of BCa (2) with increased EMT
transcription factors (EMT-TFs) including Snail, Zeb-1, Twist and Slug, and altered expression of
factors involved in cell–cell interaction such as E-cadherin, N-cadherin, and vimentin. Multiple
lines of evidence indicate that epigenetic regulation play an important role in BCa cell EMT (3).
A better understanding of the underlying epigenetic mechanisms of EMT in BCa will not only
enhance our understanding of BCa progression but also provide potential therapeutic strategies.
Lysine-specific demethylase 1 (LSD1; also known as AOF2 or KDM1a) can function as either
a transcriptional activator or a transcriptional repressor. By demethylating histone 3 lysine 4
(H3K4), LSD1 represses gene expression transcriptionally (4, 5). On the other hand, LSD1-
mediated demethylation of H3K9 promotes transcriptional activation (6). Therefore, LSD1 can
simultaneously up- and down-regulate the expression of a wide spectrum of genes involved in a
variety of biologic processes such as proliferation, stem cell pluripotency, embryonic development,
and EMT (7–11). In the cancers of the prostate (12), lung (13), ovarian (14), and colon (15), LSD1
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serves as a key positive regulator of EMT and associate with
poor prognosis. Our previous studies found that elevated levels
of LSD1 were highly associated with the grades of BCa (16).
However, the role of LSD1 in EMT and BCa progression is
largely unknown.
In this study, we demonstrated that LSD1 promotes BCa cell
EMT by upregulating LEF1. Based on the fact that the levels of
LSD1 are highly associated with cancer grades, metastasis status,
prognosis, and inhibition of LSD1 significantly repressed BCa cell
proliferation, we propose that the levels of LSD1 can serve as a
prognostic biomarker and targeting LSD1 could be a promising
therapeutic strategy for BCa treatment.
MATERIALS AND METHODS
Patients and Bladder Cancer Specimens
All patient samples were collected by the Department of
Pathology with approval from the Research Ethics Committee of
Daping Hospital, Army Military Medical University and written
informed consent was obtained from each patient. All procedures
involving human participants were carried out in accordance
with the ethical standards of the institutional research committee
and with the 1964 Helsinki Declaration and its later amendments
or comparable ethical standards. A total of 122 formalin-fixed,
paraffin-embedded samples from bladder cancer patients were
collected and used for tissue microarray (TMA) in this study.
Among them, 15 samples were excluded because no tumor
cells were identified. Therefore, 107 specimens were further
analyzed, including 24 low-grade non-muscle-invasive bladder
cancer (NMIBC), 68 high-grade muscle-invasive bladder cancer
(MIBC), and 15 Lymph node (LN)metastatic tissue samples from
high-grade MIBC patients. In addition, 12 pairs of BCa tissues
and pair-matched histologically normal tissues were collected for
WB. Another 20 pairs of BCa tissue specimens before and after
intravesical instillation or neoadjuvant therapy were collected for
IHC. All the clinical information of the patients was supplied in
Supplementary Tables S1–S3.
Animal Studies
All nude mice and severe combined immune deficiency NPG/Vst
mice with an average age of 6–8 weeks were purchased and bred
by the Division of Laboratory Animal Medicine at ArmyMedical
University. All work performed on animals were in accordance
with international laws (EEC Council Directive 86/609, O.J. L
358. 1, December 12, 1987; Guide for the Care and Use of
Laboratory Animals, United States National Research Council,
1996) and has been approved by the Institutional Animal Care
and Use Committee at Army Medical University. Animals were
fed with standard laboratory chow with free access to tap water.
To establish the xenograft models, 2 × 106 T24 cells with or
without LSD1 knockdown in 0.1ml culture medium were mixed
with Matrigel (BD Biosciences, NO.356234) at a ratio of 1:1, and
injected subcutaneously into the flank of the nude mice. The
injections were carried out in a sterilized hood. A first-generation
patient-derived xenograft (PDX) of metastatic bladder cancer
tissue was established in the NPG mice. The mice were treated
with either vehicle or GSK2879552 (Selleck, 5 mg/kg) for 4 weeks
with the sizes of the tumors monitored every other day. Tumor
volumewasmeasured with a Vernier caliper. Then, themice were
sacrificed and the tumor tissues were harvested and fixed in 10%
formaldehyde solution and embedded in paraffin for histology
analyses. For the tail vein injection model, the nude mice were
intravenously injected in the tail vein with T24 cells with or
without LSD1 knockdown (3 × 105) per mouse. After 2 weeks,
the animals were euthanized, and the lungs were excised and
embedded in paraffin.
IHC Staining
The paraffin-embedded tissues were sectioned at 4mm thickness
and arranged on glass slides in sequence. In brief, slides were
baked at 60◦C for 6 h, followed by deparaffinization with xylene,
rehydrating in graded ethanol, and 3% hydrogen peroxide to
block the endogenous peroxidase activity. The sections were
submerged in citrate or EDTA buffer and microwaved for
antigen retrieval. Goat serum (ZSGB-BIO, China) was used
to block nonspecific background and then the sections were
incubated at 4◦C with specific primary antibodies against
LSD1 (1:100 Abcam), E-cadherin (1:500 Abcam), N-cadherin
(1:200 Proteintech), Vimentin (1:1,000 Proteintech), Twist
(1:200 Abcam), followed by the secondary antibody conjugated
with streptavidin-biotin-horseradish peroxidase complex
(Biotinylated Anti-Rabbit IgG, SP-9001; Biotinylated Anti-
Mouse IgG, SP-9002, ZSGB-BIO, China). The slides were
scanned by using a computerized image system composed
of an Olympus CCD camera (Tokyo, Japan) connected to a
Nikon eclipse Ti-s microscope (Tokyo, Japan) and captured
by NIS-Elements F3.2. All of the slides were assessed by two
urological pathologists.
Cell Culture
Human bladder cancer cell lines (T24 and BIU87) were obtained
from Cell Bank of Shanghai Institutes for Biological Sciences
(Chinese Academy of Sciences), and cultured in RPMI 1640,
supplemented with 10% fetal bovine serum (Life Technologies,
Carlsbad, CA), 100 U/ml penicillin and 100 mg/ml streptomycin
(Invitrogen) and cultured in a humidified incubator at 37◦C and
5% CO2.
Lentivirus Production and Knockdown of
LSD1 by siRNA
For LSD1 knockdown experiments, T24 and BIU87 cells were
transfected with lentiviruses Lv-shRNA-LSD1 and Lv-scramble
(SBO Medical Biotechnology, Shanghai, China). Targeting
sequences for shLSD1: CCACCTGACAGTAAGGAAT.
According to the manufacturer’s instructions, the LSD1-
specific shRNA-expressing or control lentiviruses were incubated
together with a lentiviral transfection enhancer (Polybrene
5 mg/mL, Sigma–Aldrich). T24 and BIU87 cells with LSD1
knockdown were established by screening with puromycin. In
addition, LSD1 was knocked down in T24 and BIU87 cells by
scrambled or specific siRNAs. Targeting sequences for siRNA1
of LSD1: GCTCGACAGTTACAAAGTT, siRNA2 of LSD1:
GTTGGATAATCCAAAGATT. siRNAs of LSD1 or β-catenin
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were transfected into T24 or BIU87 cells using Lipo3000
(Invitrogen) following the manufacturer’s instructions.
Cell Viability Assay
Cells were seeded into 96-well-plates and after grown to 60–75%
confluence in RPMI 1640 with 10% FBS for 48 h. The viabilities
of the cells were evaluated by using the Cell Counting Kit-8
(CCK8) assay. Briefly, at the end of the exposure, cells were
aspirated, and rinsed with PBS then treated with 10 µl/well
CCK-8 for 2 h at 37◦C. Absorbance was measured at 450 nm
spectrophotometrically (Bio-Rad, Hercules, CA, USA).
Wound Scratch Assay
Cell migration was monitored in a wound scratch assay. Briefly,
bladder cancer cells were seeded to a 6-well-plate at a density
of 2 × 105 cells/well and cultured in the medium for 24 h. A
scratch was made with a sterile 10ml pipette tip in a confluent
cell monolayer, washed with PBS, and incubated in a serum-free
medium. Images of the scratches were captured at the beginning
of the experiment and after 24 h with an inverted microscope
(CK40 F200; Olympus, Japan).
Transwell Assays
To assess cell migration and invasion in vitro, we used 24-
well transwell chambers with or without Matrigel. Cells were
trypsinized and seeded into the top chamber at a density of 5 ×
104 cells per well in 200ml Dulbecco’s modified Eagle’s medium.
The outer chambers contained 800ml of medium (10% fetal calf
serum). After incubation at 37◦C for 24 h, cells attached to the
upper surface of the membrane were carefully removed with
cotton swabs, whereas cells that reached the underside of the
chamber were fixed with 10% formalin and stained with crystal
violet for 3min at room temperature and counted.
Western Blotting and Immunoprecipitation
For Western blotting, cells were seeded in 6-well-plates 2
× 105 cells/well. Cell lysates were separated on SDS-PAGE
followed by western blotting assay with antibodies against LSD1
(1:1,000 Abcam), LEF1 (1:1,000 Abcam), Twist (1:500 Abcam),
E-cadherin (1:2,000 Abcam), N-cadherin (1:500 Proteintech),
Vimentin (1:2,000 Proteintech), and β-actin (1:5,000 Cell
Signaling). IP was performed according to the protocol. Briefly,
after cold PBS washing, 2 × 107 cells were scraped into lysis
buffer containing protease inhibitors for 30min on ice, then
sample lysis was centrifuged at 14,000 × g for 20min at 4◦C.
The supernatants were incubated with normal IgG or indicated
antibodies and protein A/G-beads. The precipitated complexes
were washed with lysis buffer and boiled for 5min in SDS sample
buffer. The antibodies used for this process are as follows: LSD1
(1:1,000 Abcam), β-catenin (1:1,000 Abcam), and anti-mouse or
-rabbit IgG (Pierce) was used as a secondary antibody.
RNA Extraction, Quantitative Real-Time
PCR
Total RNA samples from cultured cells were extracted using
Trizol reagent (Invitrogen) according to the manufacturer’s
instructions. Quantitative real-time PCR (qRT-PCR) was
performed by real-time PCR (BioRad, Hercules, CA, USA). The
fold change between target gene mRNA transcripts and control
glyceraldehyde-3 phosphate dehydrogenase (GAPDH) were
calculated and shown in the histogram. Primer sequences can
be found in Supplementary Table S4. All the experiments were
performed in triplicate.
Immunofluorescence Assay
A total of 5 × 104 Cells was seeded in the confocal dish. After
2 days of culture, the cells were washed with phosphate buffer
saline (PBS), fixed in 4% paraformaldehyde, and cell membranes
were permeabilized with 0.3% Triton X-100 solution. Next, cells
were blocked with 5% bovine serum albumin (BSA) in 1% Triton
X-100 and then blotted at 4◦C overnight with different primary
antibodies against LEF1 (1:200 CST), β-catenin (1:200 Abcam).
Fluorescence-conjugated secondary antibodies (Alexa Fluor
antibody, Life Technologies) were then added to these dishes.
Cells were further washed and the nuclei were stained with 2-(4-
Amidinophenyl)-6-indolecarbamidine dihydrochloride (DAPI)
(Sigma). These confocal dishes were visualized using a Carl Zeiss
confocal fluorescence microscope (LSM 780).
Chromatin-Immunoprecipitation Assays
and RT-PCR
The CHIP assays were performed using a magnetic CHIP kit
(Active Motif). The detailed procedure was as described in the
kit provided by the manufacturer. Briefly, cells were fixed by
1% formaldehyde, fragmented by enzymatic shearing. LSD1,
β-catenin, LEF1 antibodies from Abcam were then used for
immunoprecipitation. After washing and reverse-crosslinking,
the precipitated DNA was purified and amplified by real-time-
PCR machine. Quantitative real-time polymerase chain reaction
(RT–PCR) was performed by using the SYBR Green Master
Mix (Invitrogen) based on iCycle System (Bio-Rad). PCR data
were analyzed using Graph Pad Prism (Graph Pad Software,
San Diego, California, USA).
Statistical Analysis
GraphPad Prism 5.0 (Graph Pad Software, San Diego, California,
USA) was used for all statistical analyses. Data were presented
as means ± standard deviation (SD). If the data follow a normal
distribution, the statistical significance of differences between two
groups of data was analyzed by t-test and χ2-test, differences
among several groups were analyzed by one-way analysis of
variance followed by the Least Significant Difference (LSD)
procedure for comparison of means. For those do not fit a normal
distribution, non-parametric statistical tests were used. A P-value
of <0.05 was considered statistically significant.
RESULTS
Elevated Levels of LSD1 in BCa Are
Correlated With Poor Prognosis
Elevated levels of LSD1 in a wide spectrum of malignancies
including prostate cancer (12), colon cancer (17), lung cancer
(18), liver cancer (19), and thyroid carcinoma (20) are highly
correlated with lymph nodemetastasis and poor prognosis. Based
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on our finding that elevated levels of LSD1 were highly related
to the grades of the bladder cancers (16), we hypothesized
that LSD1 plays an oncogenic role in BCa development
and/or progression. To test our hypothesis, we first analyzed
the publicly available datasets (submitted by Dyrskjøt et al.,
E-mail:lars@clin.au.dk, available at: https://www.ncbi.nlm.nih.
gov/geo/query/acc.cgi?acc5GSE3167) in the Gene Expression
Omnibus (GEO) and found that compared to that in the
normal urothelium the levels of LSD1 are significantly higher
in both NMIBC and MIBC (Figure 1A). We then compared
the levels of LSD1 in BCa specimens with their surrounding
normal tissues from a cohort of 12 BCa patients. The levels
of LSD1 in tumor tissues are consistently higher than that
of their corresponding normal tissues albeit LSD1 expression
varies greatly among patients (Figure 1B). Next, we conducted
immunohistochemistry (IHC) staining against LSD1 on TMA
in patients with low-grade NMIBC, high-grade MIBC, and
metastatic MIBC (Figure 1C). Figure 1D showed that the level
of LSD1 is significantly elevated in high-grade and metastatic
cancers. More importantly, patients with elevated levels of LSD1
in their BCa (Figure 1E) also have shortened overall survival
(Figure 1F). These results altogether indicated that LSD1 is
associated with BCa progression and poor prognosis.
The Role of LSD1 in BCa Cell Migration,
Invasion, and Proliferation
Given that LSD1 can promote cell invasion and migration
in many cancer cells, we decided to exam if LSD1 has the
same effect in BCa cells. To do so, we first knocked down
LSD1 in both T24 and BIU87 cells by shRNAs specifically
against LSD1 and conducted RNA-Seq to identify differentially
expressed genes (DEGs) in the cells with or without LSD1
knockdown. Among the 928 DEGs, 504 and 424 were up-
and downregulated, respectively. The DEGs were then subjected
to gene ontology (GO) category and KEGG pathway analyses.
The top 15 GO categories of biological processes (BP) were
related with wound healing (Figure 2A), a process closely
relevant to EMT. Results from scratch assay showed that wound
scratch closed up much slowly when LSD1 is knocked down
(Figures 2B,C), and these findings are consistent with that from
transwell assays (Figures 2D,E). Next, we injected T24 cells with
or without LSD1 knockdown to the tail-vein of mice. Fourteen
days post-injection, mice were sacrificed and the number of
nodules in the lungs which represent the invasive capacity was
estimated. Figures 2F,G showed that knockdown LSD1 reduced
the number of lung metastasis nodules significantly. Results
from CCK-8 assays showed that the proliferation of both T24
and BIU87 cells was also repressed when LSD1 is knocked
down (Supplementary Figures S1A,B). Moreover, when cells
were injected into the flanks of nude mice to form xenograft
tumors, the weight and size of xenografts derived from T24 with
or without LSD1 knockdown demonstrated the indispensability
of LSD1 in BCa (Supplementary Figures S1C–E). These data
altogether suggested that LSD1 plays an important role in BCa
cell migration, invasion and proliferation.
LSD1 Regulates BCa EMT in vitro and
in vivo
Given that (1) EMT plays important roles in BCa progression
(2); and (2) treatments such as cisplatin, doxorubicin (21),
and mitomycin C (22) can enhance BCa cell EMT process,
we decided to explore the role of LSD1 in BCa cell EMT.
Results from q-PCR and WB showed that knockdown LSD1
resulted in a significant reduction of both mRNA (Figure 3A)
and protein (Figures 3B,C) levels of the mesenchymal markers
N-cadherin, Vimentin, and Twist with elevated levels of
the epithelial marker E-cadherin. Meanwhile, upregulated N-
cadherin, Vimentin, and Twist and downregulated E-cadherin
were seen in tumors formed in the lungs (Figure 3D). These
findings were further substantiated by the IHC results of
the xenografts derived from T24 with or without LSD1
knockdown (Figure 3E). All these results suggested that LSD1
plays an important role in BCa cell EMT in vivo. Then,
we conducted IHC staining of BCa specimens collected from
20 patients before and after chemotherapy. The 10 patients
with NMIBC were treated with local intravesical instillation
and Supplementary Figure S2A showed that local intravesical
instillation with gemcitabine induced BCa cell EMT evidenced
by up-regulated mesenchymal markers (N-cadherin, Vimentin,
and Twist) and down-regulated epithelium marker E-cadherin.
Of note, elevated levels of LSD1 were seen in samples post
local intravesical instillation. Another 10 patients with MIBC
were treated with neo-adjuvant systemic chemotherapy and
Supplementary Figure S2B showed that systemic chemotherapy
also resulted in increased mesenchymal phenotype and reduced
epithelial phenotype evidenced by upregulated mesenchymal
markers (N-cadherin, Vimentin, and Twist) and downregulated
epithelium marker E-cadherin. More importantly, LSD1 is
also upregulated by systemic chemotherapy. These results
suggested that either local intravesical installation or systemic
chemotherapy can induce BCa cell EMT and LSD1 plays an
indispensable role in this process.
LSD1 Regulates LEF1 by Forming a
Complex With β-Catenin
RNA-Seq showed that LSD1 is highly involved in both wound
healing (Figure 2A) and cancer development (Figure 4A).
Intriguingly, LEF1 appeared to be involved in all top five
pathways as shown in the Venn diagram (Figure 4B). Given the
important role of LEF1 in EMT and LSD1 is enriched at the
transcriptional start site of the LEF1 gene in breast cancer (23),
we focused our attention on LSD1-regulated LEF1 in BCa. To
confirm the RNAseq results, we conducted immunofluorescence
staining on T24 and BIU87 cells and found that LEF1 is
much less expressed when LSD1 is knocked down (Figure 4C).
Then, qPCR and WB were conducted on T24 and BIU87
cells when LSD1 is knocked down by two different siRNAs.
Both the mRNA and the protein (Figure 4D) levels of LEF1
were significantly downregulated when LSD1 is knocked down.
To determine the role of LEF1 in LSD1-enhanced BCa EMT,
we overexpressed LEF1 by transient transfection of a plasmid
expressing LEF1 in T24 and BIU87 cells with LSD1 knockdown.
Figure 4E showed that LEF1 is successfully expressed in these
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FIGURE 1 | Elevated levels of LSD1 in bladder cancer are correlated with poor prognosis. (A) Datasets from Gene Expression Omnibus (GEO) showed that LSD1 was
relatively highly expressed in BCs tissues than normal urothelium. (B) 12 pairs of BCa tissues and pair-matched histologically normal tissues were estimated by WB.
(C,D) Representative H&E staining and IHC results for LSD1 in the TMA from bladder cancer patients. (E,F) The overall survival of 107 patients with LSD1high or
LSD1low BCa was analyzed by the log-rank test. *P < 0.05.
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FIGURE 2 | LSD1 promotes the migration, invasion, and proliferation of bladder cancer cell. (A) The top 15 GO categories of biological process (BP) of RNA-Seq
result. (B) Expression of LSD1 analyzed by Western blotting and RT-qPCR after transfection with shRNA for LSD1 in T24 and BIU87 cells. (C) Cells were seeded in
6-well-plates in growth media and cultured for 24 h. Cell migration was estimated by scratch-wound healing assay. (D,E) T24 cells with or without LSD1 knockdown
were seeded in 24-well transwell chambers with or without Matrigel in growth media and cultured for 48 h. Cell migration (D) and invasion (E) were estimated.
(F,G) H&E stained section of lung showing metastatic lesions collected 14 days after the injection of T24 cells with or without LSD1 knockdown into the tail vein of
nude mice. A significant reduction in lung metastasis between the two cohorts can be observed. Quantifications were shown on right (G). *P < 0.05.
cells and the overexpressed LEF1 is capable of rescuing the
downregulated mesenchymal markers N-cadherin, Vimentin,
and Twist and upregulated epithelial marker E-cadherin resulted
from LSD1 knockdown, strongly suggesting the role of LSD1 in
BCa EMT is LEF1-dependent. Given the fact that Wnt/β-catenin
transcriptionally regulates LEF1 (24, 25) and LSD1 is enriched
at the transcriptional start site of the LEF1 gene in breast cancer
(23), we speculated that LSD1may regulate LEF1 in BCa by cross-
talking with β-catenin. We first conducted immunoprecipitation
assays and showed that LSD1 and β-catenin can precipitate each
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FIGURE 3 | LSD1 regulates BCa EMT in vivo and in vitro. (A–C) T24 cells with or without LSD1 knockdown were seeded in 6-well-plates and cultured for 48 h; mRNA
and protein levels of EMT markers E-Cadherin, N-Cadherin, Vimentin, and Twist were determined by quantitative RT-PCR and Western blotting. The data represent
means ± S.D. *P < 0.05. (D) Lungs collected from T24 cells with or without LSD1 knockdown tail vein injected model of nude mice were conducted IHC staining with
antibodies against E-cadherin, N-cadherin, Vimentin and Twist. (E) Tumors collected from T24 cells with or without LSD1 knockdown subcutaneous xenograft model
of nude mice treated as indicated were conducted IHC staining with antibodies against E-cadherin, N-cadherin, Vimentin, and Twist.
other reciprocally in both T24 and BIU87 cells (Figure 4F).
These results were further substantiated by immunoprecipitation
assays with the lysate of 293T cells when Flag-tagged LSD1
and HA-tagged β-catenin were co-expressed (Figure 4G). More
importantly, the recruitment of LSD1 on LEF1 promoter is
significantly reduced when either LSD1 or β-catenin were
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FIGURE 4 | LSD1 regulates LEF1 by forming a complex with β-catenin. (A) The top 15 pathways of RNA-Seq result. (B) Venn diagram showed that the overlapping
gene among the top five pathways was LEF1. (C) Confocal microscopy was used to determine the LEF1 protein expression in T24 cells with or without LSD1
knockdown. (D) Expression of LEF1 analyzed by RT-qPCR after transfection with shRNA or siRNAs for LSD1 in T24 and BIU87 cells. Expression of LEF1 analyzed by
Western blotting after transfection with shRNA or siRNAs for LSD1 in T24 and BIU87 cells. (E) EMT markers were determined by Western blotting in T24 and BIU87
cells with LSD1 knockdown when the expression of LEF1 was rescued by transient transfection of a plasmid expressing LEF1. The data represent means ± S.D. *P <
0.05. (F) T24 and BIU87 cells were lysed and subjected to co-immunoprecipitation with LSD1 and β-catenin antibodies. (G) 293T cells were transfected with indicated
plasmids. co-immunoprecipitation was conducted by using Flag and HA antibodies, immunoblot was analyzed with the above antibodies. (H) T24 cells with or without
LSD1 knockdown were subjected to CHIP assays with LSD1 antibody. (I) T24 cells with or without β-catenin knockdown were subjected to CHIP assays with LSD1
antibody. (J) T24 cells with or without LSD1 knockdown were subjected to CHIP assays with H3K4me1, H3K4me2, H3K9me1, and H3K9me2 antibodies.
knocked down (Figures 4H,I) suggesting the essentiality of β-
catenin in the recruitment of LSD1. Since knockdown LSD1 has
also remarkably increased the levels of H3K4me1, H3K4me2,
H3K9me1, and H3K9me2 on the promoter region of LEF1
(Figure 4J), we conclude that LSD1’s demethylase activity is
indispensable for LEF1 upregulation. These data altogether
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FIGURE 5 | Inhibiting LSD1 attenuates BCa cell proliferation in vivo. (A,B) T24 and BIU87 cells with or without GSK were seeded in 96-well-plates with 1 × 103 cells
per well in growth media cultured for 7 days. Cell viabilities were estimated by CCK8 every other day. (C–H) Nude mice bearing T24 cell-derived or patient-derived
xenograft (PDX) metastatic bladder cancer tissue was treated with or without GSK2879552 for 4 weeks; the tumors were measured and weighed. The data represent
means ± S.D. *P < 0.05. (I) Xenografts collected were conducted IHC staining with antibodies against Ki67 (proliferation marker) and Bcl-2 (apoptosis marker).
(J) Patient-derived xenograft (collected were conducted IHC staining with antibodies against Ki67 and Bcl-2. (K) Schematic model of the hypothesized mechanism by
which LSD1 promotes EMT development.
demonstrated that in BCa cells LSD1 complexes with β-catenin
and to upregulate LEF1 transcriptionally. Upregulated LEF1, in
turn, mediates LSD-enhanced EMT by regulating the expression
of specific epithelial and mesenchymal markers.
Inhibiting LSD1 Attenuates BCa Cell
Proliferation in vivo
It has been reported that LSD1 inhibitor GSK287955 can repress
proliferation of both AML and small-cell lung cancer (SCLC)
cells in vitro and the growth of NCI-H1417 SCLC xenograft
in vivo (18, 26). We decided to test if GSK2879552 can inhibit
LSD1-mediated BCa progression. Results from CCK-8 assays
showed that proliferation of both T24 and BIU87 cells is inhibited
by GSK2879552 (Figures 5A,B). Then, T24 cells were injected
subcutaneously into nude mice and the tumors were allowed
to grow for 10 days. The mice were treated with either vehicle
or GSK2879552 (5 mg/kg) for 4 weeks with the sizes of the
tumors monitored every other day. The tumors in mice treated
Frontiers in Oncology | www.frontiersin.org 9 July 2020 | Volume 10 | Article 1234
Xie et al. LSD1 Promotes EMT
with GSK2879552 are not only much smaller but also weigh
much lesser (Figures 5C–E). Finally, we estimated the effect of
GSK2879552 in the patient-derived xenograft (PDX)model using
metastatic BCa tissues and found that GSK2879552 is capable
of inhibiting the growth of PDX significantly (Figures 5F–H).
Furthermore, the results of IHC showed the levels of Ki67 and
Bcl-2 in xenografts derived from either cancer cells or PDX
were also inhibited by GSK2879552 (Figures 5I,J). These data
altogether suggest that inhibiting LSD1 by GSK2879552 could be
a promising therapeutic strategy in BCa treatment.
DISCUSSION
BCa is one of the most frequently diagnosed cancers and
its treatment remains a great challenge (27). Although it
is well-accepted that EMT plays a crucial role in the
progression of BCa and epigenetic regulation is important in
EMT progress, the precise underlying mechanisms are largely
unknown. We found in this research that LSD1 is capable
of enhancing EMT process and BCa cancer progression by
complexing with β-catenin to transcriptionally upregulate LEF1
(Figure 5K). We also demonstrated that targeting LSD1 by
specific inhibitor GSK2879552 could be a new therapeutic
strategy for BCa treatment.
EMT is involved in numerous biological and pathological
processes including embryonic development, wound healing,
cancer cell metastasis, and drug resistance (28). For cancer cells,
loss of apical-basal polarity, cell-cell adhesion, and transit to
invasive mesenchymal cells ultimately leads to intravasation (29).
Poor prognosis is frequently accompanied by enhanced EMT
in different cancers, including pancreatic cancer, breast cancer
(30), and lung cancer (31, 32). It has been suggested that EMT
is also a crucial process in BCa progression and metastasis (2).
Non-muscle-invasive BCa carries a high risk of progressing to
muscle-invasive BCa. This process is accompanied by decreased
E-cadherin expression, suggesting that EMT is involved in the
progression in BCa (10). We demonstrated that knockdown of
LSD1 inhibited EMT process evidenced by increased protein
levels of E-cadherin and decreased mRNA and protein levels
of N-cadherin, Vimentin and Twist in tumor cell lines in vitro
and xenograft in vivo. In addition, we showed that intravesical
instillation and neoadjuvant therapy can upregulate LSD1 and
EMT in BCa cells, and these findings are in accordance with that
fact that EMT could be induced by treatments such as cisplatin,
doxorubicin, and mitomycin C (21).
Epigenetic modifications play important roles in different
diseases (33) and overexpression of LSD1 correlates with the
invasion, migration, metastasis, and poor clinical outcome of
different cancers (34–37), and EMT is closely correlated with the
migration and invasion of various types of tumors (38). Although
most studies show that LSD1 can enhance EMT, the underlying
molecular mechanisms in BCa is unclear. In this study, we
demonstrated that LSD1 is associated with BCa malignant
potential progression and poor prognosis. We also propose
that in BCa cells the LSD1-regulated EMT markers is LEF1-
dependent because (1) knockdown LSD1 not only interrupted
the expression of EMT markers but also downregulated LEF1,
and (2) overexpressed LEF1 can rescue the expression of EMT
markers in LSD1 knockdown cells. These findings are in line with
the reports that LEF1 is highly involved in both tumorigenesis
and EMT (39, 40). In addition, pharmacological inhibition
or knockdown of LSD1 significantly decreased migration and
invasion of cancers in the colon (15), prostate (12), lung (13), and
ovarian (14). In this study, we demonstrated that GSK2879552
is capable of repressing tumor progression of both T24- and
patient-derived xenograft. Since both preclinical and clinical data
(18, 41) indicate that GSK2879552 is a strong antitumor reagent
with acceptable tolerability and safety profile in patients with
advanced cancers including small-cell lung cancer (SCLC) and
AML, we propose that inhibiting LSD1 by GSK2879552 could be
a potential therapeutic option for patients with BCa.
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